Among patients treated for 12 weeks with grazoprevir plus elbasvir without ribavirin , 97 % ( 95 % CI 82-100 , 28/29 ) of patients in cohort 1 and 91 % ( 76-98 , 30/33 ) of patients in cohort 2 achieved SVR12 .